Sai Life Sciences Ltd's Q3FY25 Quarter Results
- 07 Feb 2025
Result Summary
- Sai Life Sciences Ltd reported a - quarter-on-quarter (QoQ) - in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a - of -.
- Its expenses for the quarter were - by - QoQ and - - YoY.
- The net profit - - QoQ and - - YoY.
- The earnings per share (EPS) of Sai Life Sciences Ltd stood at 2.8 during Q3FY25.
Financial Statments for Q3FY25
| (₹ crores) | Q3FY25 | Q2FY25 | Q3FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 448.89 | 0.00 | 0.00 | - | - |
Total Expenses | 377.24 | 0.00 | 0.00 | - | - |
Profit Before Tax | 71.65 | - | - | NaN% | NaN% |
Tax | 17.80 | 0.00 | 0.00 | - | - |
Profit After Tax | 53.85 | 0.00 | 0.00 | - | - |
Earnings Per Share | 2.80 | 0.00 | 0.00 | - | - |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Sai Life Sciences Ltd is a leading contract research and development and manufacturing organization (CRDMO) known for its services in the pharmaceutical industry. The company primarily focuses on offering end-to-end services to pharmaceutical companies, including drug discovery, development, and commercial manufacturing. Recent major developments for Sai Life Sciences Ltd include expansions of their manufacturing capabilities and strategic partnerships to enhance their service offerings. As a player in the pharmaceutical industry, the company is part of a sector that is heavily regulated and driven by innovation and patent cycles. Information regarding specific recent developments or events in the past year is not available in the provided data.
Revenue
For the third quarter of the fiscal year 2025 (Q3FY25), Sai Life Sciences Ltd reported a total income of ₹448.89 crores. This figure is presented without prior quarter (Q2FY25) or year-on-year (Q3FY24) comparative data, therefore, it is not possible to calculate the quarter-over-quarter (QoQ) or year-over-year (YoY) changes. The revenue metric indicates the company's total earnings from its business operations during the specified period, which serves as a fundamental indicator of its financial health and market performance.
Profitability
During Q3FY25, Sai Life Sciences Ltd recorded a profit before tax of ₹71.65 crores. The tax expense for the quarter stood at ₹17.80 crores, leading to a profit after tax of ₹53.85 crores. The earnings per share for the period was ₹2.80. As with revenue, there are no prior period data points available for direct comparison to identify trends or calculate QoQ and YoY changes. The profitability is a crucial measure that reflects the company’s capability to generate earnings relative to its expenses and taxes incurred during the quarter.
Operating Metrics
The financial data indicates total expenses of ₹377.24 crores for Q3FY25. With the absence of comparative data from previous quarters or years, QoQ and YoY changes cannot be calculated. The lack of additional operating metrics such as operating income, cash flow, or specific segment performance limits a more detailed operational analysis. However, the existing data provides a snapshot of the company's operations and cost management during the quarter, which is essential for understanding its operational efficiency.
